Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
A Three-year, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability in Patients With Active Lupus Nephritis
Sponsor: Novartis Pharmaceuticals
Terminated
Study terminated by sponsor based on a futility analysis of the core study CAIN457Q12301
Other terminated trials from Novartis Pharmaceuticals
Other Lupus Nephritis trials with similar outcome
This PHASE3 trial investigates Lupus Nephritis and is currently terminated or withdrawn. Novartis Pharmaceuticals leads this study, which shows 12 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Terminated PHASE3
-
Feb 2025 — Jun 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Feb 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
▶ Show 7 earlier versions
-
Mar 2024 — Jul 2024 [monthly]
Terminated PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Terminated PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
Oct 2023 — Jan 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2022 — Jul 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .